Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotic Effect on Seizure Frequency in Drug-Resistant Epilepsy
NCT05160350Phase 4Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Apr 2021
- Primary completion
- Oct 2021
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Familact 2 Plus in epilepsy (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoint: Change in seizure frequency at 12 weeks. Started Apr 2021; status: completed.
02
Drugs
Familact 2 Plus
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT05160350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05160350.